Tag: SIG-002
Lilly wraps up Sigilon Therapeutics acquisition to amplify Type 1 diabetes research
Eli Lilly and Company (Lilly) has formally announced the culmination of its $309.6 million takeover of biopharma trailblazer, Sigilon Therapeutics, Inc. (NASDAQ: SGTX). This strategic ... Read More
Lilly to transform chronic disease management with Sigilon Therapeutics acquisition
Pharmaceutical giant Eli Lilly and Company (Lilly) has announced its definitive agreement to acquire Nasdaq-listed biopharma innovator Sigilon Therapeutics, in a move set to significantly ... Read More